Test Price
2,800 AED✅ Home Collection Available
IL1RAPL1 Gene Intellectual Disability, X‑linked Type 21 (MRX21) Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
✔ 99.9% Diagnostic Sensitivity via ISO‑accredited Next‑Generation Sequencing.
✔ VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (Daily 8 AM – 11 PM).
✔ Telephonic Post‑Test Clinical Guidance by a DHA‑licensed Consultant Medical Geneticist.
✔ Instant Insurance Billing Verification via WhatsApp +971 54 548 8731.
✔ Full‑Gene NGS Coverage Including Splice Sites and Copy Number Variants.
✔ Pre‑Test Genetic Counselling with Pedigree Review and Clinical History Assessment.
✔ Comprehensive Clinical Report Signed by a Board‑Certified Geneticist.
✔ DHA‑Licensed Facility (License No. 1143) – Dubai Healthcare City.
Test Overview & Methodology
The IL1RAPL1 NGS test detects pathogenic and likely pathogenic variants in the IL1RAPL1 gene responsible for X‑linked intellectual disability type 21 (MRX21). This single‑gene analysis employs high‑depth next‑generation sequencing to interrogate all coding exons, flanking splice junctions, and conserved non‑coding regulatory regions. The assay is validated for germline variant detection including single‑nucleotide variants, small insertions and deletions, and copy number variants. Results are interpreted in accordance with ACMG/AMP guidelines and correlated with the patient’s neurological phenotype and three‑generation pedigree.
| Feature | Our Test (NGS Full‑Gene Sequencing) | Closest Alternative (Microarray / Limited Panel) |
|---|---|---|
| Methodology | NGS – complete coding region, splice sites, deep intronic regions, and CNV detection | Chromosomal microarray or targeted exon panel; often misses deep intronic variants and small CNVs |
| Diagnostic Yield | >99% sensitivity for known pathogenic variants within covered regions | 70–85% depending on platform; cannot reliably detect all IL1RAPL1 mutations |
| Turn‑Around Time | 3 to 4 Weeks | 4 to 6 Weeks |
| Pre‑Test Genetic Counselling | Included – pedigree chart and clinical history reviewed before sample acceptance | Often limited or offered as a separate service |
| Accreditation | ISO 9001:2015, DHA‑Licensed Facility (No. 1143) | Varies; may not hold UAE‑specific regulatory approvals |
| Price | 2800 AED | 2000 – 3500 AED |
Physician Insight & Safety Protocols
“Interpretation of IL1RAPL1 variants demands rigorous integration of the patient’s developmental history, neurological examination findings, and three‑generational family tree. A negative sequencing result does not exclude intellectual disability arising from mutations in other X‑linked or autosomal genes. Comprehensive pre‑test and post‑test genetic counselling is indispensable to address incidental findings, carrier status in female relatives, and recurrence risks in future pregnancies.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Advisory Precautions for Patients and Families
⚠️ Important Notice: Do not alter, pause, or discontinue any prescribed neurological, behavioural, or psychiatric medication without consulting your treating physician. Genetic test results supplement, but do not replace, ongoing clinical management and multidisciplinary care.
Exclusion Criteria & Emergency Red Flags
Contraindications and Safety Alerts
- Bleeding Risk: Known severe coagulopathy (e.g., haemophilia, platelet dysfunction) – use dried blood spot on FTA card or buccal swab alternative only; venipuncture is contraindicated.
- Local Infection: Active cellulitis, dermatitis, or open wound at the intended phlebotomy site – defer blood draw until resolution.
- Paediatric Consent: For minors under 18 years, written parental or legal guardian consent is mandatory under Federal Decree‑Law No. 4 of 2016 on Medical Liability; child‑friendly home collection is available with age‑appropriate distraction techniques.
- Emergency Response: If syncope, expanding haematoma, or vasovagal shock occurs during or after venipuncture, seek immediate medical attention.
- Variant Interpretation: Variants of uncertain significance (VUS) must be reviewed by a board‑certified clinical geneticist; never use a VUS alone for therapeutic or reproductive decision‑making.
Patient FAQ & Clinical Guidance
1. What is the turnaround time for the IL1RAPL1 NGS test in the UAE?
The complete workflow – from DNA extraction and library preparation through high‑depth sequencing, bioinformatic analysis, and clinical reporting – requires 3 to 4 weeks at our DHA‑licensed laboratory. Home‑collected samples transported in validated cold‑chain containers are processed on the same schedule and do not incur additional delay.
2. How is the sample collected for this genetic test?
A routine venous blood draw (3–5 ml in an EDTA vacutainer) is the standard specimen. For patients who prefer or require a non‑invasive option, a dried blood spot on an FTA card is acceptable. Our VIP Mobile Phlebotomy service visits your home daily from 8 AM to 11 PM across all seven Emirates, using sterile equipment and strict UAE infection‑control protocols. All samples are transported in temperature‑controlled cold‑chain packaging to preserve nucleic acid integrity.
3. Will my UAE health insurance cover the cost of this test?
We provide instant direct billing verification via WhatsApp at +971 54 548 8731 to confirm your policy coverage before any financial commitment. Many UAE insurers cover single‑gene NGS testing for intellectual disability when pre‑authorised with appropriate clinical justification. Our billing team handles the entire approval process, submitting the relevant ICD‑10 codes (F79, Q99.8, Z13.79) and supporting medical history on your behalf.
4. What does the clinical report include?
The final report documents all detected variants with their genomic coordinates, predicted protein effect, population frequency, and ACMG classification (pathogenic, likely pathogenic, VUS, likely benign, or benign). A concise clinical interpretation correlates the genotype with the patient’s phenotype, provides carrier risk assessment for female relatives, and offers management recommendations. The report is co‑signed by a Consultant Medical Geneticist and includes references to peer‑reviewed literature.
5. Can this test detect carrier status in asymptomatic female relatives?
Yes. Because IL1RAPL1 follows an X‑linked inheritance pattern, female carriers are typically asymptomatic or may present with mild cognitive features. The NGS assay detects heterozygous variants with high sensitivity. Pre‑test genetic counselling is strongly recommended for at‑risk female family members to discuss the implications of carrier results for their own health and for reproductive planning.
UAE Regulatory & Data Privacy Adherence
This genetic testing service operates in full compliance with the UAE federal legislative framework governing health data and patient safety. All genomic and personal data are processed, stored, and transmitted under the provisions of Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical consent, sample collection, and reporting procedures adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability. The laboratory is licensed by the Dubai Health Authority (Facility No. 1143) and holds ISO 9001:2015 certification. Physical facility: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE.
Clinical & Logistical Metadata
| Test Name | IL1RAPL1 Gene Intellectual Disability, X‑linked Type 21 (MRX21) – NGS Full‑Gene Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3 to 4 Weeks |
| Sample Type / Matrix | Peripheral Whole Blood (EDTA) or Dried Blood Spot (FTA Card) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection |
| Methodology Used | Next‑Generation Sequencing (NGS) – Full coding exons, splice sites, deep intronic regions, and CNV analysis |
| ICD-10-CM Code | F79, Q99.8, Z13.79 |
| LOINC Code | 94222-8 |
| DHA Facility License & Laboratory Address | License No. 1143 – Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians